NCT04894656|Withdrawn
Study Stopped
Study withdrawn due to funding.
Intestinal Permeability and Gastroparesis
Assessing Intestinal Barrier Function and Permeability in Patients With Gastroparesis
Loading search results
Study withdrawn due to funding.
Assessing Intestinal Barrier Function and Permeability in Patients With Gastroparesis
Sponsor study identifier
interventional
0
0 countries
N/A
Study Start
April 1, 2022
Actual (reported)Primary Completion
July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The purpose of this study is to investigate potential mechanisms that could lead to the development of a condition known as gastroparesis.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 11, 2021
Actual (reported)May 20, 2021
Actual (reported)April 1, 2022
Actual (reported)July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Assess duodenal epithelial tight junction structure in GP patients using confocal laser endomicroscopy.
through study completion, approximately 3-4 days
Assess small intestinal permeability using the lactulose:mannitol urinary excretion test.
through study completion, approximately 3-4 days
Measure serum levels of immune markers (e.g., IL-1,4,6,10,12,13,18; zonulin, CRP, TNF-alpha, tryptase,) in GP patients and compare to healthy controls.
One time measurement
Quantitate different duodenal cell types (e.g., mast cells (CK117), eosinophils, enterochromaffin, intraepithelial lymphocytes (IELs) and CCK-containing cells) in patients with GP using biopsies from both the D1 and D2 duodenal segments.
through study completion, approximately 3-4 days
Assess the relationship of GP symptoms to intestinal permeability, using validated questionnaires, and to histopathological changes.
through study completion, approximately 3-4 days
Tests to assess intestinal permeability
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
David Cangemi, MD
Mayo Clinic
0 participants (actual enrollment reported by the registry).
First Submitted
May 11, 2021
First Posted
May 20, 2021
Study Start
April 1, 2022
Actual (reported)A Study to Evaluate the Influence of Diet on GI Health
Contact the study team to confirm eligibility.
Primary Completion
July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
July 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 19, 2023
Record last verified: 2023-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: